Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 257,511
  • Shares Outstanding, K 33,883
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,740 K
  • 60-Month Beta 1.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.75
  • Number of Estimates 5
  • High Estimate -0.73
  • Low Estimate -0.78
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -63.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.14 +6.44%
on 03/22/19
8.92 -14.80%
on 04/08/19
-0.94 (-11.01%)
since 03/18/19
3-Month
5.17 +47.00%
on 01/29/19
9.25 -17.84%
on 02/25/19
+1.71 (+29.03%)
since 01/18/19
52-Week
4.03 +88.59%
on 12/24/18
17.39 -56.30%
on 05/14/18
-8.44 (-52.62%)
since 04/18/18

Most Recent Stories

More News
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 7.60 (-0.26%)
Research Report Identifies Dean Foods, Kala Pharmaceuticals, Buckeye Partners, Rockwell Medical, United Fire Group, and Clearwater Paper with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dean Foods Company (NYSE:DF),...

DF : 2.12 (+0.95%)
RMTI : 4.75 (unch)
UFCS : 42.58 (+0.64%)
KALA : 7.60 (-0.26%)
BPL : 33.15 (-0.45%)
CLW : 19.55 (+0.21%)
Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 7.60 (-0.26%)
Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

Kala Pharmaceuticals (KALA) needs investors to pay close attention to the stock based on moves in the options market lately.

KALA : 7.60 (-0.26%)
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

--August 15, 2019 Prescription Drug User Fee Act (PDUFA) target action date for KPI-121 0.25% for the temporary relief of signs and symptoms of dry eye disease

KALA : 7.60 (-0.26%)
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 7.60 (-0.26%)
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 7.60 (-0.26%)
ACTO Emerges as a Leader in Life Sciences Commercialization; Closes Strong Calendar Year 2018 with 184% Revenue Growth and Doubled Customer Base

ACTO Technologies Inc. emerged as a leader in life sciences commercialization by closing a strong calendar year 2018 with 184% revenue growth and a doubled customer base. This past year, ACTO secured global,...

KALA : 7.60 (-0.26%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 7.60 (-0.26%)
Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

JPM : 113.46 (-0.73%)
KALA : 7.60 (-0.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade KALA with:

Business Summary

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes,...

See More

Key Turning Points

2nd Resistance Point 7.89
1st Resistance Point 7.74
Last Price 7.60
1st Support Level 7.36
2nd Support Level 7.12

See More

52-Week High 17.39
Fibonacci 61.8% 12.29
Fibonacci 50% 10.71
Fibonacci 38.2% 9.13
Last Price 7.60
52-Week Low 4.03

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar